Source: Annual Congress 2007 - Interstitial lung disease: diagnostic and therapeutic novelties
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Ricci, P. Bruno, L. Pisani, L. Tabbì, S. Giovagnoli, S. Mariotta (Rome, Italy). Clinical significance of serum CA 15-3 in patients with idiopathic interstitial pneumonias. Eur Respir J 2007; 30: Suppl. 51, 1573

Member's Comments

No comment yet.

Related content which might interest you: Prognostic significance of serum markers in acute exacerbation of idiopathic interstitial pneumonias Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011 Clinical significance of histological classification of idiopathic interstitial pneumonia Source: Eur Respir J 2002; 19: 275-283 Year: 2002 Diagnostic mistakes in patients with idiopathic interstitial pneumonias (IIP) Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Clinical value of cluster analysis of unclassifiable idiopathic interstitial pneumonias phenotypes Source: Virtual Congress 2020 – What is hot in idiopathic pulmonary fibrosis? Year: 2020 The clinical significance of markers of endothelial dysfunction (ED) inprogression of idiopathic interstitial pneumonias (IIP) Source: Annual Congress 2011 - Cell biology of lung disease Year: 2011 Biopsy documented idiopathic interstitial pneumonias - Analysis of diagnostic yield, survival and mortality over 9 years Source: Annual Congress 2013 –Interventional procedures for diagnosis of diffuse lung diseases and peripheral pulmonary lesions Year: 2013 Prevalence and clinical characteristics of unclassifiable idiopathic interstitial pneumonias (IIPs) Source: International Congress 2017 – Novel and old entities Year: 2017 Clinical-radiographic-pathologic diagnosis in idiopathic interstitial pneumonia (IIP) Source: Eur Respir J 2002; 20: Suppl. 38, 61s Year: 2002 Impact of BAL lymphocytosis > 15% on the prognosis of chronic idiopathic interstitial pneumonias other than idiopathic pulmonary fibrosis: a retrospective nationwide study based on multidisciplinary discussion Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 ProSP-B as a possible biomarker in idiopathic interstitial pneumonias (ILD) Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Ca 19-9 serum levels in patients with end-stage Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Clinical categorisation of idiopathic interstitial pneumonias Source: Research Seminar 2004 - Genotyping and Phenotyping of Diffuse Parenchymal Lung Diseases Year: 2004 Incidence, clinical pictures and courses of patients with MPO-ANCA positive interstitial pneumonia (IP) of unknown etiology Source: Eur Respir J 2004; 24: Suppl. 48, 505s Year: 2004 Clinical significance of autoantibody screening in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia Source: Eur Respir J 2002; 19: 1114-1118 Year: 2002 Clinical experience with nintedanib for the treatment of IPF in 80 cases Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Prognostic factors analysis of patients with acute exacerbation of idiopathic interstitial pneumonias treated by polymyxin B hemoperfusion Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Diagnosis and treatment of new idiopathic interstitial pneumonias cases: Analysis using the Japanese Registry. Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Non-specific interstitial pneumonia (NSIP) - a study of 12 patients Source: Eur Respir J 2002; 20: Suppl. 38, 60s Year: 2002